Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 30, 2008
Event: Completion of the disposition of the Union Biometrica division, including its German subsidiary, Union Biometrica GmbH. This transaction represents the sale of the remaining portion of the Company's Capital Equipment Business Segment.
Key Financial Metrics and Transaction Terms
Transaction Structure: Asset Purchase Agreement with UBIO Acquisition Company (principals: David Strack and Christopher Bogan, former Union Biometrica management).
- Upfront Consideration: $1 in cash plus assumption of certain liabilities by the Buyer.
- Earn-out Consideration: Based on revenue generated by the acquired business over a five-year post-transaction period.
- 5% of revenue up to and including $6,000,000 annually.
- 8% of revenue above $6,000,000 annually.
- Payment Terms: Earn-out amounts evidenced by interest-bearing promissory notes due September 30, 2013, or earlier based on triggering events.
Financial Statements: The filing references pro forma consolidated financial information (Exhibit 99.1) but does not provide specific revenue, profit, cash flow, or debt figures within the text of this report.
Material Changes and Restrictions
The sale of the Union Biometrica division marks a material change in the Company's operations, effectively exiting the Capital Equipment Business Segment. The Asset Purchase Agreement includes significant restrictive covenants:
- Non-Competition: The Company and its subsidiaries are prohibited from engaging in the business of making or selling products made or sold by Union Biometrica (as of the 12-month period prior to closing) for five years.
- Non-Solicitation: The Company cannot induce or attempt to induce officers or employees of the Buyer to leave their employment for five years.
Guidance, Outlook, and Risks
Management Commentary: The filing summarizes the material terms of the agreement and notes that the sale occurred simultaneously with the signing of the Asset Purchase Agreement. No specific forward-looking guidance or outlook regarding future financial performance is provided in this text.
Risks and Contingencies: Future consideration is contingent upon the revenue performance of the sold business under new ownership. The Company's future financial results will be impacted by the removal of the Capital Equipment Business Segment, as detailed in the referenced pro forma information.
Investor Verification Checklist
- Review Exhibit 99.1 for pro forma consolidated financial information to understand the impact of the divestiture on the Company's financial position.
- Examine Exhibit 2.1 (Asset Purchase Agreement) for the full text of representations, warranties, indemnification provisions, and specific triggering events for early note repayment.
- Verify the specific liabilities assumed by the Buyer to assess any remaining contingent obligations for Harvard Bioscience.
- Monitor future filings for the calculation and payment of the earn-out promissory notes over the five-year period.